Edmonton, Canada

Feridoun Karimi-Busheri

USPTO Granted Patents = 2 


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2017

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Inventor Feridoun Karimi-Busheri: Contributions to Biopharmaceutical Innovations

Introduction

Feridoun Karimi-Busheri is a notable inventor located in Edmonton, CA, recognized for his contributions to the field of biopharmaceuticals. With two patents to his name, he has significantly advanced the development of small molecule inhibitors with promising therapeutic applications.

Latest Patents

Karimi-Busheri's latest patents focus on small molecule inhibitors of polynucleotide kinase/phosphatase and poly(ADP-ribose) polymerase. These inventions primarily relate to the use of these compounds as chemosensitizers and/or radiosensitizers. The patents outline the provision of pharmaceutical combinations and/or pharmaceutically acceptable salts, as well as kits and methods for utilizing these innovative compounds.

Career Highlights

Throughout his career, Feridoun Karimi-Busheri has worked with reputable organizations, including the Governors of the University of Alberta and Alberta Health Services. His research and extensive expertise in biochemistry and pharmacology have solidified his reputation in the field.

Collaborations

Karimi-Busheri has collaborated with esteemed colleagues such as Michael Weinfeld and Dennis Hall. Their collective efforts have enhanced the depth and impact of research initiatives aimed at developing advanced therapeutic solutions.

Conclusion

Feridoun Karimi-Busheri continues to make substantial contributions to the world of biopharmaceutical chemistry through his innovative patents and collaborative research efforts. His work is instrumental in paving the way for new treatment modalities that can potentially improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…